You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 125 No. 2, February 2007 TABLE OF CONTENTS
  Archives
  •  Online Features
  Laboratory Sciences
 This Article
 •Full text
 •PDF
 • Reply to article
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Citing articles on ISI (3)
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Topic Collections
 •Genetics
 •Genetic Counseling/ Testing/ Therapy
 •Neurology
 •Neuro-ophthalmology
 •Articles for Residents
 •Ophthalmological Disorders, Other
 •Alert me on articles by topic

Use of Mitochondrial Antioxidant Defenses for Rescue of Cells With a Leber Hereditary Optic Neuropathy–Causing Mutation

Xiaoping Qi, MD; Liang Sun, PhD; William W. Hauswirth, PhD; Alfred S. Lewin, PhD; John Guy, MD

Arch Ophthalmol. 2007;125(2):268-272.

Objective  To explore a treatment paradigm for Leber hereditary optic neuropathy (LHON), we augmented mitochondrial antioxidant defenses to rescue cells with the G11778A mutation in mitochondrial DNA.

Methods  Cells homoplasmic for the G11778A mutation in mitochondrial DNA were infected with an adeno-associated viral vector containing the human mitochondrial superoxide dismutase (SOD2) gene. Control cells were infected with an adeno-associated viral (AAV) vector expressing the green fluorescent protein (GFP). Two days later, the high-glucose culture medium was exchanged for a glucose-free medium containing galactose. After 1 or 2 days, cellular production of superoxide was assessed using the fluorescent probe dihydroethidium, and we used TUNEL (terminal deoxynucleotidyl transferase–mediated biotin–deoxyuridine triphosphate nick-end labeling) staining to detect apoptotic nuclei. The effect of SOD2 on LHON cell survival was quantitated after 2 or 3 days.

Results  Comparisons of AAV-SOD2–infected LHON cells relative to control cells infected with AAV–green fluorescent protein showed increased expression of mitochondrial SOD that attenuated superoxide-induced fluorescence by 26% (P = .003) and suppressed TUNEL-induced fluorescence by 21% (P = .048) after 2 days of growth in galactose medium, when cell survival increased by 25% (P=.05). After 3 days in galactose medium, SOD2 increased LHON survival by 89% (P = .006) relative to controls.

Conclusion  Protection against mitochondrial oxidative stress may be useful for treatment of LHON.

Clinical Relevance  Gene therapy with antioxidant genes may protect patients with LHON against visual loss.


Author Affiliations: Departments of Ophthalmology (Drs Qi, Sun, Hauswirth, and Guy), Molecular Genetics and Microbiology (Drs Hauswirth and Lewin), and Neurology (Dr Guy), College of Medicine, University of Florida, Gainesville.



THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

From the Library
Br. J. Ophthalmol. 2007;91:704-704.
FULL TEXT  

Genetic Ophthalmology and the Era of Clinical Care
Sieving and Collins
JAMA 2007;297:733-736.
FULL TEXT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 2007 American Medical Association. All Rights Reserved.